Invivoscribe(R) Launches Four CE-Marked NGS-Based LymphoTrack(R) Dx Assays
21. April 2015 08:07 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Apr 21, 2015) - Invivoscribe Technologies, Inc. (IVS) announced today the commercial release of four CE-marked LymphoTrack® Dx next-generation sequencing (NGS)...
Genection anuncia lançamento do MyAML(TM), um ensaio Next Generation Sequencing (NGS - Sequenciamento da Próxima Geração) para Leucemia Mieloide Aguda
17. März 2015 12:50 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Mar 17, 2015) -
A Genection(TM), Inc., uma subsidiária da Invivoscribe Technologies(R), Inc., anunciou hoje o lançamento do MyAML(TM), um ensaio de...
Genection anuncia el lanzamiento de MyAML(TM), un ensayo de secuenciación de próxima generación (NGS) para leucemia mieloide aguda
17. März 2015 12:50 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Mar 17, 2015) -
Genection(TM), Inc., una subsidiaria de Invivoscribe Technologies(R), Inc., anunció hoy que ha lanzado MyAML(TM), un ensayo de secuenciación...
Genection Announces Launch of MyAML(TM), a Next Generation Sequencing (NGS) Assay for Acute Myeloid Leukemia
17. März 2015 06:00 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Mar 17, 2015) - Genection™, Inc., a subsidiary of Invivoscribe Technologies®, Inc., announced today that it has launched MyAML™, a CLIA validated next...
Invivoscribe FLT3 Verfahrenspatentansprüche Bestätigt
18. Juli 2013 00:04 ET
|
Invivoscribe
SAN DIEGO, CA--(Marketwired - Jul 18, 2013) - Invivoscribe Technologies, Inc. ("Invivoscribe") hat erfolgreich seine Verfahrensansprüche, die den Kern des Europäischen Patents, welches...
Se apoyaron las reclamaciones de patente de métodos FLT3 de Invivoscribe
16. Juli 2013 13:10 ET
|
Invivoscribe
SAN DIEGO, CA--(Marketwired - Jul 16, 2013) -
Invivoscribe Technologies, Inc. ("Invivoscribe") ha defendido con éxito las reclamaciones de métodos en la base de las patentes...
Reivindicação de Patente do Método Invivoscribe FLT3 aceita
16. Juli 2013 09:53 ET
|
Invivoscribe
SAN DIEGO, CA--(Marketwired - Jul 16, 2013) -
Invivoscribe Technologies, Inc. ("Invivoscribe") defendeu com sucesso as reivindicações do método da parte central das patentes...
Invivoscribe FLT3 Method Patent Claims Upheld
16. Juli 2013 00:01 ET
|
Invivoscribe
SAN DIEGO, CA--(Marketwired - Jul 16, 2013) - Invivoscribe Technologies, Inc. ("Invivoscribe") has successfully defended the method claims at the core of international patents covering FLT3...
Patentes de pruebas FLT3 de Invivoscribe fortalecidas por dictamen de la Corte Suprema
19. Juni 2013 14:09 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Jun 19, 2013) -
En el asunto de Association of Molecular Pathology c. Myriad, la Corte Suprema de los Estados Unidos rechazó las reclamaciones de patentes de...
Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling
19. Juni 2013 08:36 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Jun 19, 2013) - In Association of Molecular Pathology v. Myriad, the U.S. Supreme Court struck down BRCA1 and BRCA2 gene patent claims. It is important for the...